SB-699551

SB-699551 is a drug which was the first compound developed to act as a selective antagonist for the serotonin receptor 5-HT5A, with selectivity of around 100x over other serotonin receptor subtypes.[1] Multiple therapeutic roles have been suggested for 5-HT5A ligands due to the presence of this receptor in several areas of the brain, but research is still at an early stage,[2] In animal studies, SB-699551 was found to block cue-mediated responding to LSD, again suggesting an antipsychotic type of activity.[3] It also reduces the viability of certain types of cancer cells in vitro, suggesting the 5-HT5A receptor as a possible target for novel chemotherapy drugs.[4][5]

SB-699551
Identifiers
  • 3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-([(2-phenylethyl)amino]methyl)-4-biphenylyl)methyl]propanamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC34H45N3O
Molar mass511.754 g·mol−1
3D model (JSmol)
  • C2CCCC2CCC(=O)N(CCN(C)C)Cc(cc3)ccc3-c(cc1)ccc1CNCCc4ccccc4
  • InChI=1S/C34H45N3O/c1-36(2)24-25-37(34(38)21-16-28-10-6-7-11-28)27-31-14-19-33(20-15-31)32-17-12-30(13-18-32)26-35-23-22-29-8-4-3-5-9-29/h3-5,8-9,12-15,17-20,28,35H,6-7,10-11,16,21-27H2,1-2H3
  • Key:SEQAMPXQRKYYQF-UHFFFAOYSA-N
  (verify)

References
  1. Thomas DR, Soffin EM, Roberts C, Kew JN, de la Flor RM, Dawson LA, et al. (September 2006). "SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain". Neuropharmacology. 51 (3): 566–577. doi:10.1016/j.neuropharm.2006.04.019. PMID 16846620. S2CID 543423.
  2. Nikiforuk A, Hołuj M, Kos T, Popik P (June 2016). "The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia". Neuropharmacology. 105: 351–360. doi:10.1016/j.neuropharm.2016.01.035. PMID 26826431. S2CID 31557477.
  3. Popik P, Krawczyk M, Kuziak A, Bugno R, Hogendorf A, Staroń J, Nikiforuk A (November 2019). "Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats". Journal of Psychopharmacology. 33 (11): 1447–1455. doi:10.1177/0269881119867603. PMID 31452444. S2CID 201733534.
  4. Itsumi M, Shiota M, Sekino Y, Ushijima M, Kashiwagi E, Takeuchi A, et al. (August 2020). "High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer". The Prostate. 80 (11): 885–894. doi:10.1002/pros.24022. PMID 32483877. S2CID 219174471.
  5. Gwynne WD, Shakeel MS, Girgis-Gabardo A, Kim KH, Ford E, Dvorkin-Gheva A, et al. (August 2020). "Antagonists of the serotonin receptor 5A target human breast tumor initiating cells". BMC Cancer. 20 (1): 724. doi:10.1186/s12885-020-07193-6. PMC 7404930. PMID 32758183.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.